Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Total Non-Current Liabilities (2023 - 2025)

Historic Total Non-Current Liabilities for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $6.6 million.

  • BioLineRx's Total Non-Current Liabilities fell 6574.84% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year decrease of 6574.84%. This contributed to the annual value of $10.0 million for FY2024, which is 2678.71% up from last year.
  • BioLineRx's Total Non-Current Liabilities amounted to $6.6 million in Q3 2025, which was down 6574.84% from $7.7 million recorded in Q2 2025.
  • BioLineRx's Total Non-Current Liabilities' 5-year high stood at $25.4 million during Q2 2023, with a 5-year trough of $6.6 million in Q3 2025.
  • For the 3-year period, BioLineRx's Total Non-Current Liabilities averaged around $14.1 million, with its median value being $10.0 million (2024).
  • Per our database at Business Quant, BioLineRx's Total Non-Current Liabilities skyrocketed by 2678.71% in 2024 and then crashed by 6574.84% in 2025.
  • Over the past 3 years, BioLineRx's Total Non-Current Liabilities (Quarter) stood at $7.9 million in 2023, then rose by 26.79% to $10.0 million in 2024, then crashed by 34.24% to $6.6 million in 2025.
  • Its Total Non-Current Liabilities was $6.6 million in Q3 2025, compared to $7.7 million in Q2 2025 and $8.6 million in Q1 2025.